Dr. Reddy’s gets exclusive commercialization rights in the United States (U.S.) as well as semi-exclusive rights in Europe and United Kingdom (UK)
Data support the potential of Dupixent as the first new treatment approach in more than a decade and first-ever targeted therapy for COPD
EBITDA for the quarter stood at Rs 964 crore, representing an EBITDA margin of 24%
U.S. FDA has informed Moderna that due to administrative constraints, the agency will not complete its review of mRNA-1345 by the PDUFA date of May 12, 2024
Outlook 2024 remains flat CER sales growth and CORE EBITDA margin of high 20s
Subcutaneous nivolumab has potential to be the first and only subcutaneously administered PD-1 inhibitor
TIVDAK is the first antibody-drug conjugate (ADC) to have positive overall survival data for patients with previously treated recurrent or metastatic cervical cancer
New data for Tezspire and Breztri demonstrate AstraZeneca’s innovation and commitment to transform care in COPD
Sales reflect continued strong growth in oncology and vaccines
Submission based on results from pivotal phase III trial showing all primary endpoints met
Subscribe To Our Newsletter & Stay Updated
